Brought to you by 
Pfizer to buy Sanofi's Campto if Aventis buyout happens
17 Jun 2014
Executive Summary
Contingent upon the successful takeover of Aventis by Sanofi-Synthelabo, Pfizer will acquire worldwide exclusive rights (outside of Japan) to Sanofi's (now Aventis's) colorectal cancer drug Campto (irinotecan) for €510mm ($620mm).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to buy Sanofi's Campto if Aventis buyout happens
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice